# Iker Huerga

> Iker Huerga is the CEO of Pathos AI, a New York- and Chicago-based biotech building what it calls the first true AI-enabled drug development platform for oncology. A data scientist by training with more than two decades at the intersection of machine learning and cancer research, he previously served as Chief Data Scientist for Oncology R&D at AstraZeneca and as an EVP at Tempus Labs, and founded three oncology companies with two successful exits. He took the helm at Pathos in May 2025, days before the company closed a $365 million Series D that valued it at roughly $1.6 billion, with a stated mission to get the right therapies to the right patients, sooner.

- **Role:** Chief Executive Officer at Pathos AI
- **Organizations:** Pathos AI, AstraZeneca, Tempus Labs
- **Nationality:** Spanish (Basque)
- **Education:** Mondragon University (Mondragon Unibertsitatea)
- **Known for:** Appointed CEO of Pathos AI in May 2025 to lead its AI-enabled drug development platform., Founded three oncology companies with two successful exits., Served as Chief Data Scientist for Oncology R&D at AstraZeneca.

## Career timeline

- **Early career** — Founded and led oncology-focused technology companies, building three companies over his career with two successful exits.
- **Tempus era** — Served as Executive Vice President at Tempus Labs, working on data engineering and strategy in precision oncology.
- **AstraZeneca** — Served as Chief Data Scientist for Oncology R&D, applying multimodal AI to clinical trial design, biomarker discovery, and precision medicine.
- **2025-05** — Appointed CEO and Board Member of Pathos AI, succeeding interim CEO Ryan Fukushima.
- **2025-05** — Pathos AI closed a $365M Series D financing at a roughly $1.6B valuation.

## Achievements

- Appointed CEO of Pathos AI in May 2025 to lead its AI-enabled drug development platform.
- Founded three oncology companies with two successful exits.
- Served as Chief Data Scientist for Oncology R&D at AstraZeneca.
- Served as Executive Vice President at Tempus Labs.
- Recognized for pioneering work applying multimodal AI to clinical trial design, biomarker discovery, and precision medicine.
- Published research indexed on Google Scholar in machine learning and optimization.

## Latest updates

- **2025-05** — Named CEO and Board Member of Pathos AI, succeeding interim CEO Ryan Fukushima.
- **2025-05** — Pathos AI closed a $365M Series D financing round at a roughly $1.6B valuation.

## Links

- Website: https://www.pathos.com
- LinkedIn: https://www.linkedin.com/in/ikerhuerga/

---

Profile page: https://yespress.io/iker-huerga
Published by YesPress — https://yespress.io
Last updated: 2026-07-17